The FDA has approved the supplemental Abbreviated New Drug Application (sANDA) for Orphengesic Forte.
Researchers assessed the incidence rate and type of serious adverse events in children with inflammatory rheumatic diseases receiving tocilizumab.
Authors of a report presented the case of systemic sclerosis-polymyositis overlap syndrome in an adolescent with anti-Ku antibodies.
From 2005 to 2016, skeletal muscle relaxant (SMR) use increased in the United States.
Researchers evaluated blood pressure dipping as a marker of endothelial function and subclinical atherosclerosis in pediatric-onset systemic lupus erythematosus.
The FDA has approved Hulio® (adalimumab-fkjp; Mylan), a biosimilar to Humira® (adalimumab; AbbVie).
A new systemic inflammatory syndrome, “Kawa-COVID-19,” may be associated with SARS-CoV-2 infection in children.
COVID-19 generally causes mild disease in children, with 8% of children requiring intensive care unit admission.
The American College of Rheumatology has issued clinical guidance to rheumatology providers for the management of pediatric patients with rheumatic disease during the COVID-19 pandemic.
Researchers evaluated disease course and long-term efficacy of methotrexate treatment in children with linear scleroderma.